多基因评分在2型糖尿病中的临床应用:挑战与可能
2型糖尿病具有高度异质性,全基因组关联研究已报道超过1200个相关变异,遗传数据成本下降促进了多基因评分的发展。本综述总结了不同 ancestry 中2型糖尿病相关多基因评分的现有知识,探讨其在预测、筛查和风险分层中的可能临床作用,并讨论全球适用性的挑战。目前多基因评分的临床效用有限,其预测效果不及临床指标;未来价值可能在于疾病严重程度分层和治疗反应,而非预测2型糖尿病风险。
要点
- 全基因组关联研究已报道超过1200个与2型糖尿病相关的变异。
- 目前多基因评分对2型糖尿病的临床效用有限,预测效果不及临床指标。
- 未来多基因评分的价值可能在于疾病严重程度分层和治疗反应,而非预测风险。
核心结论
- 目前多基因评分对2型糖尿病的临床效用有限,其预测效果不及临床指标。
- 未来多基因评分的价值可能在于疾病严重程度(合并症风险)分层和治疗反应,而非预测2型糖尿病风险。
研究设计与样本
- 本综述总结了不同 ancestry 中2型糖尿病相关多基因评分的现有知识,并探讨其可能的临床作用。
主要发现
- 全基因组关联研究已报道超过1200个与2型糖尿病相关的变异。
- 遗传数据生成成本下降促进了多基因评分的发展,该评分基于组合大多数或所有遗传变异的影响来估计个体遗传疾病风险。
- 大多数遗传风险位点来自欧洲血统人群,其他 ancestry 代表性不足。
临床怎么用
- 原文未据此给出推荐。
局限性
- 大多数遗传风险位点来自欧洲血统人群,而其他 ancestry 代表性不足,讨论了其全球适用性的挑战。
- 目前多基因评分对2型糖尿病的临床效用有限,其预测效果不及临床指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resulting from a combination of genetic and environmental factors, type 2 diabetes is highly heterogeneous in manifestation and disease progression, with the only common feature being chronic hyperglycaemia. In spite of vigorous efforts to elucidate the pathogenetic origins and natural course of the disease, there is still a lack of biomarkers and tools for prevention, disease stratification and treatment. Genome-wide association studies have reported over 1200 variants associated with type 2 diabetes, and the decreased cost of generating genetic data has facilitated the development of polygenic scores for estimating an individual's genetic disease risk based on combining effects from most-or all-genetic variants. In this review, we summarise the current knowledge on type 2 diabetes-related polygenic scores in different ancestries and outline their possible clinical role. We explore the potential applicability of type 2 diabetes polygenic scores to quantify genetic liability for prediction, screening and risk stratification. Given that most genetic risk loci are determined from populations of European origin while other ancestries are under-represented, we also discuss the challenges around their global applicability. To date, the potential for clinical utility of polygenic scores for type 2 diabetes is limited, with such scores outperformed by clinical measures. In the future, rather than predicting risk of type 2 diabetes, the value of polygenic scores may be in stratification of the severity of disease (risk for comorbidities) and treatment response, in addition to aiding in dissecting the pathophysiological mechanisms involved.
引用
- Prasad RB, Hakaste L, Tuomi T, et al. Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities. Diabetologia. 2025. PMID: 40186687. doi:10.1007/s00125-025-06419-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。